drugset / Trial / NCT01033747

Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study

NCT01033747

Phase 2/3 Completed 70 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and the effects on liver iron of Deferasirox when given for a long treatment period in patients with transfusion dependent iron overload.

Timeline

Start
2003-02
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferasirox Unknown 5 mg/kg Oral
Subject Deferasirox Unknown 10 mg/kg Oral
Subject Deferasirox Unknown 30 mg/kg Oral